Intellia Therapeutics Q3 2026 Results: Net Loss of $127M, Loss Widens
Intellia Therapeutics reported a net loss of $127.5 million for the third quarter of 2026, driven by a decrease in collaboration revenue and increased general and administrative expenses. The company strengthened its balance sheet during the nine months ended September 30, 2026, through a follow-on public offering and new debt issuance, resulting in total cash, cash equivalents, and marketable securities of approximately $614.8 million.
- Key figure
- Net loss $127M